Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review
Aims Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping...
Gespeichert in:
| Veröffentlicht in: | Diabetic medicine 2022-05, Vol.39 (5), p.e14741-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 5 |
| container_start_page | e14741 |
| container_title | Diabetic medicine |
| container_volume | 39 |
| creator | Knoll, Christine Peacock, Sofia Wäldchen, Mandy Cooper, Drew Aulakh, Simran Kaur Raile, Klemens Hussain, Sufyan Braune, Katarina |
| description | Aims
Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping to understand their safety and effectiveness.
Methods
A systematic review of real‐world studies on the effect of commercial and open‐source AID system use on clinical outcomes was conducted employing a devised protocol (PROSPERO ID 257354).
Results
Of 441 initially identified studies, 21 published 2018–2021 were included: 12 for Medtronic 670G; one for Tandem Control‐IQ; one for Diabeloop DBLG1; two for AndroidAPS; one for OpenAPS; one for Loop; three comparing various types of AID systems. These studies found that several types of AID systems improve Time‐in‐Range and haemoglobin A1c (HbA1c) with minimal concerns around severe hypoglycaemia. These improvements were observed in open‐source and commercially developed AID systems alike.
Conclusions
Commercially developed and open‐source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real‐world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness. |
| doi_str_mv | 10.1111/dme.14741 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2597496517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2597496517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-d736a977a78723dfe72067d1243681e1e90a135259a7a8c961d7dac37b4a0d593</originalsourceid><addsrcrecordid>eNp1kc9uFSEUh4nR2NvqwhcwJG7sYlrOwAyDu6bWP0mNidE14cK5SsPAODDe3J2P4DP4aD6JtPfqwkQ2kPCd7xz4EfIE2BnUde5GPAMhBdwjKxC9aDqh4D5ZMSnahjMJR-Q45xvGoFVcPSRHXEjJOYMV-fkBTfj1_cc2zcFR_OYdRos0RWqDj96aQNNSbBox07ShE6YpIN368oWW3YQUqPNmjaVeL9nHzzRNGKsvp2WuHhMdrcUjztZXlVlKGk1BR33MS21AXbqryrtccMwv6MXhaIq3dK7z4PYRebAxIePjw35CPr26-nj5prl-__rt5cV1Y_kwQOMk742S0shBttxtULaslw5awfsBEFAxA7xrO2WkGazqwUlnLJdrYZjrFD8hz_feaU5fF8xFjz5bDMFETEvWtVIK1XcgK_rsH_SmvjfW6XTbd4y39XNvhad7ys4p5xk3epr9aOadBqZvg9M1OH0XXGWfHozLekT3l_yTVAXO98DWB9z936RfvrvaK38Dho6luQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2650323309</pqid></control><display><type>article</type><title>Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Knoll, Christine ; Peacock, Sofia ; Wäldchen, Mandy ; Cooper, Drew ; Aulakh, Simran Kaur ; Raile, Klemens ; Hussain, Sufyan ; Braune, Katarina</creator><creatorcontrib>Knoll, Christine ; Peacock, Sofia ; Wäldchen, Mandy ; Cooper, Drew ; Aulakh, Simran Kaur ; Raile, Klemens ; Hussain, Sufyan ; Braune, Katarina</creatorcontrib><description>Aims
Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping to understand their safety and effectiveness.
Methods
A systematic review of real‐world studies on the effect of commercial and open‐source AID system use on clinical outcomes was conducted employing a devised protocol (PROSPERO ID 257354).
Results
Of 441 initially identified studies, 21 published 2018–2021 were included: 12 for Medtronic 670G; one for Tandem Control‐IQ; one for Diabeloop DBLG1; two for AndroidAPS; one for OpenAPS; one for Loop; three comparing various types of AID systems. These studies found that several types of AID systems improve Time‐in‐Range and haemoglobin A1c (HbA1c) with minimal concerns around severe hypoglycaemia. These improvements were observed in open‐source and commercially developed AID systems alike.
Conclusions
Commercially developed and open‐source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real‐world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness.</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.14741</identifier><identifier>PMID: 34773301</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>automated insulin delivery ; automated insulin dosing ; Automation ; Blood Glucose ; Blood Glucose Self-Monitoring ; Clinical outcomes ; Clinical trials ; Diabetes ; diabetes mellitus ; Diabetes mellitus (insulin dependent) ; Diabetes Mellitus, Type 1 - drug therapy ; diabetes technology ; Dosage ; Female ; Hemoglobin ; Humans ; Hypoglycemia ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin - therapeutic use ; Insulin Infusion Systems ; Male ; open‐source ; real‐world evidence ; Reviews ; Systematic review ; type 1 diabetes</subject><ispartof>Diabetic medicine, 2022-05, Vol.39 (5), p.e14741-n/a</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd on behalf of Diabetes UK.</rights><rights>2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-d736a977a78723dfe72067d1243681e1e90a135259a7a8c961d7dac37b4a0d593</citedby><cites>FETCH-LOGICAL-c3881-d736a977a78723dfe72067d1243681e1e90a135259a7a8c961d7dac37b4a0d593</cites><orcidid>0000-0003-0404-517X ; 0000-0003-3847-8416 ; 0000-0002-1580-7144 ; 0000-0002-0842-1737 ; 0000-0001-6611-8245 ; 0000-0001-7376-3365 ; 0000-0001-6590-245X ; 0000-0001-8229-5081</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdme.14741$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdme.14741$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34773301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knoll, Christine</creatorcontrib><creatorcontrib>Peacock, Sofia</creatorcontrib><creatorcontrib>Wäldchen, Mandy</creatorcontrib><creatorcontrib>Cooper, Drew</creatorcontrib><creatorcontrib>Aulakh, Simran Kaur</creatorcontrib><creatorcontrib>Raile, Klemens</creatorcontrib><creatorcontrib>Hussain, Sufyan</creatorcontrib><creatorcontrib>Braune, Katarina</creatorcontrib><title>Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review</title><title>Diabetic medicine</title><addtitle>Diabet Med</addtitle><description>Aims
Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping to understand their safety and effectiveness.
Methods
A systematic review of real‐world studies on the effect of commercial and open‐source AID system use on clinical outcomes was conducted employing a devised protocol (PROSPERO ID 257354).
Results
Of 441 initially identified studies, 21 published 2018–2021 were included: 12 for Medtronic 670G; one for Tandem Control‐IQ; one for Diabeloop DBLG1; two for AndroidAPS; one for OpenAPS; one for Loop; three comparing various types of AID systems. These studies found that several types of AID systems improve Time‐in‐Range and haemoglobin A1c (HbA1c) with minimal concerns around severe hypoglycaemia. These improvements were observed in open‐source and commercially developed AID systems alike.
Conclusions
Commercially developed and open‐source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real‐world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness.</description><subject>automated insulin delivery</subject><subject>automated insulin dosing</subject><subject>Automation</subject><subject>Blood Glucose</subject><subject>Blood Glucose Self-Monitoring</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>diabetes technology</subject><subject>Dosage</subject><subject>Female</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Male</subject><subject>open‐source</subject><subject>real‐world evidence</subject><subject>Reviews</subject><subject>Systematic review</subject><subject>type 1 diabetes</subject><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc9uFSEUh4nR2NvqwhcwJG7sYlrOwAyDu6bWP0mNidE14cK5SsPAODDe3J2P4DP4aD6JtPfqwkQ2kPCd7xz4EfIE2BnUde5GPAMhBdwjKxC9aDqh4D5ZMSnahjMJR-Q45xvGoFVcPSRHXEjJOYMV-fkBTfj1_cc2zcFR_OYdRos0RWqDj96aQNNSbBox07ShE6YpIN368oWW3YQUqPNmjaVeL9nHzzRNGKsvp2WuHhMdrcUjztZXlVlKGk1BR33MS21AXbqryrtccMwv6MXhaIq3dK7z4PYRebAxIePjw35CPr26-nj5prl-__rt5cV1Y_kwQOMk742S0shBttxtULaslw5awfsBEFAxA7xrO2WkGazqwUlnLJdrYZjrFD8hz_feaU5fF8xFjz5bDMFETEvWtVIK1XcgK_rsH_SmvjfW6XTbd4y39XNvhad7ys4p5xk3epr9aOadBqZvg9M1OH0XXGWfHozLekT3l_yTVAXO98DWB9z936RfvrvaK38Dho6luQ</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Knoll, Christine</creator><creator>Peacock, Sofia</creator><creator>Wäldchen, Mandy</creator><creator>Cooper, Drew</creator><creator>Aulakh, Simran Kaur</creator><creator>Raile, Klemens</creator><creator>Hussain, Sufyan</creator><creator>Braune, Katarina</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0404-517X</orcidid><orcidid>https://orcid.org/0000-0003-3847-8416</orcidid><orcidid>https://orcid.org/0000-0002-1580-7144</orcidid><orcidid>https://orcid.org/0000-0002-0842-1737</orcidid><orcidid>https://orcid.org/0000-0001-6611-8245</orcidid><orcidid>https://orcid.org/0000-0001-7376-3365</orcidid><orcidid>https://orcid.org/0000-0001-6590-245X</orcidid><orcidid>https://orcid.org/0000-0001-8229-5081</orcidid></search><sort><creationdate>202205</creationdate><title>Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review</title><author>Knoll, Christine ; Peacock, Sofia ; Wäldchen, Mandy ; Cooper, Drew ; Aulakh, Simran Kaur ; Raile, Klemens ; Hussain, Sufyan ; Braune, Katarina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-d736a977a78723dfe72067d1243681e1e90a135259a7a8c961d7dac37b4a0d593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>automated insulin delivery</topic><topic>automated insulin dosing</topic><topic>Automation</topic><topic>Blood Glucose</topic><topic>Blood Glucose Self-Monitoring</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>diabetes technology</topic><topic>Dosage</topic><topic>Female</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Male</topic><topic>open‐source</topic><topic>real‐world evidence</topic><topic>Reviews</topic><topic>Systematic review</topic><topic>type 1 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knoll, Christine</creatorcontrib><creatorcontrib>Peacock, Sofia</creatorcontrib><creatorcontrib>Wäldchen, Mandy</creatorcontrib><creatorcontrib>Cooper, Drew</creatorcontrib><creatorcontrib>Aulakh, Simran Kaur</creatorcontrib><creatorcontrib>Raile, Klemens</creatorcontrib><creatorcontrib>Hussain, Sufyan</creatorcontrib><creatorcontrib>Braune, Katarina</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knoll, Christine</au><au>Peacock, Sofia</au><au>Wäldchen, Mandy</au><au>Cooper, Drew</au><au>Aulakh, Simran Kaur</au><au>Raile, Klemens</au><au>Hussain, Sufyan</au><au>Braune, Katarina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review</atitle><jtitle>Diabetic medicine</jtitle><addtitle>Diabet Med</addtitle><date>2022-05</date><risdate>2022</risdate><volume>39</volume><issue>5</issue><spage>e14741</spage><epage>n/a</epage><pages>e14741-n/a</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><abstract>Aims
Several commercial and open‐source automated insulin dosing (AID) systems have recently been developed and are now used by an increasing number of people with diabetes (PwD). This systematic review explored the current status of real‐world evidence on the latest available AID systems in helping to understand their safety and effectiveness.
Methods
A systematic review of real‐world studies on the effect of commercial and open‐source AID system use on clinical outcomes was conducted employing a devised protocol (PROSPERO ID 257354).
Results
Of 441 initially identified studies, 21 published 2018–2021 were included: 12 for Medtronic 670G; one for Tandem Control‐IQ; one for Diabeloop DBLG1; two for AndroidAPS; one for OpenAPS; one for Loop; three comparing various types of AID systems. These studies found that several types of AID systems improve Time‐in‐Range and haemoglobin A1c (HbA1c) with minimal concerns around severe hypoglycaemia. These improvements were observed in open‐source and commercially developed AID systems alike.
Conclusions
Commercially developed and open‐source AID systems represent effective and safe treatment options for PwD of several age groups and genders. Alongside evidence from randomized clinical trials, real‐world studies on AID systems and their effects on glycaemic outcomes are a helpful method for evaluating their safety and effectiveness.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34773301</pmid><doi>10.1111/dme.14741</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-0404-517X</orcidid><orcidid>https://orcid.org/0000-0003-3847-8416</orcidid><orcidid>https://orcid.org/0000-0002-1580-7144</orcidid><orcidid>https://orcid.org/0000-0002-0842-1737</orcidid><orcidid>https://orcid.org/0000-0001-6611-8245</orcidid><orcidid>https://orcid.org/0000-0001-7376-3365</orcidid><orcidid>https://orcid.org/0000-0001-6590-245X</orcidid><orcidid>https://orcid.org/0000-0001-8229-5081</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0742-3071 |
| ispartof | Diabetic medicine, 2022-05, Vol.39 (5), p.e14741-n/a |
| issn | 0742-3071 1464-5491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2597496517 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | automated insulin delivery automated insulin dosing Automation Blood Glucose Blood Glucose Self-Monitoring Clinical outcomes Clinical trials Diabetes diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 - drug therapy diabetes technology Dosage Female Hemoglobin Humans Hypoglycemia Hypoglycemic Agents - therapeutic use Insulin Insulin - therapeutic use Insulin Infusion Systems Male open‐source real‐world evidence Reviews Systematic review type 1 diabetes |
| title | Real‐world evidence on clinical outcomes of people with type 1 diabetes using open‐source and commercial automated insulin dosing systems: A systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A08%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90world%20evidence%20on%20clinical%20outcomes%20of%20people%20with%20type%201%20diabetes%20using%20open%E2%80%90source%20and%20commercial%20automated%20insulin%20dosing%20systems:%20A%20systematic%20review&rft.jtitle=Diabetic%20medicine&rft.au=Knoll,%20Christine&rft.date=2022-05&rft.volume=39&rft.issue=5&rft.spage=e14741&rft.epage=n/a&rft.pages=e14741-n/a&rft.issn=0742-3071&rft.eissn=1464-5491&rft_id=info:doi/10.1111/dme.14741&rft_dat=%3Cproquest_cross%3E2597496517%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2650323309&rft_id=info:pmid/34773301&rfr_iscdi=true |